COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
Conditions
Brief summary
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning \>94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after an mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such, several countries including the United States, Israel and Chile have recommended a third vaccine dose for high-risk populations. However, it is not currently known which is the best vaccine combination regarding immunogenicity, particularly in these vulnerable patients. This observational study will explore the humoral and cellular response to a SARS-CoV-2 BNT162b2 vaccine booster in solid organ transplant patients who received two previous doses of the inactivated Coronavac or two doses of BNT162b2 vaccines.
Interventions
BIOLOGICALThree doses of SARS-CoV-2 BNT162b2 vaccine (observational)
Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.
BIOLOGICALTwo doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.
Sponsors
Pontificia Universidad Catolica de Chile
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Solid organ transplant patients in the last 10 years and currently under immunosuppressive therapy * Vaccination with two doses of Coronavac vaccine or BNT162b2 vaccines, followed by a booster dose (3d dose) of BNT162b2 vaccine administered in the previous 8-12 weeks.
Exclusion criteria
* Previous SARS-CoV-2 infection * Booster vaccine (3rd dose) administered less than 8 weeks or more than 12 weeks before enrolment * Intravenous immunoglobulin therapy 60 days before enrolment * Previous SARS-CoV-2 vaccine different from CoronaVac or BNT162b2
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IgG seropositivity 8-12 weeks after third dose BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of positive neutralizing antibodies 8 to 12 weeks after third dose BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
| Neutralizing geometric mean titers 8 to 12 weeks after third dose of BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
Other
| Measure | Time frame |
|---|---|
| The number of IFN-y-spot forming T cells SARS-CoV-2 specific after third dose of BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
Countries
Chile
Outcome results
None listed